nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—Homicidal ideation—Varenicline—nicotine dependence	0.0977	0.138	CcSEcCtD
Levomilnacipran—CYP2J2—Fatty acids—CYP2A7—nicotine dependence	0.044	0.158	CbGpPWpGaD
Levomilnacipran—CYP2J2—Xenobiotics—CYP2A7—nicotine dependence	0.0349	0.126	CbGpPWpGaD
Levomilnacipran—Anger—Varenicline—nicotine dependence	0.0343	0.0485	CcSEcCtD
Levomilnacipran—Night sweats—Varenicline—nicotine dependence	0.0227	0.0321	CcSEcCtD
Levomilnacipran—Suicidal ideation—Varenicline—nicotine dependence	0.0175	0.0247	CcSEcCtD
Levomilnacipran—Mania—Varenicline—nicotine dependence	0.0169	0.0238	CcSEcCtD
Levomilnacipran—Extrapyramidal disorder—Varenicline—nicotine dependence	0.0163	0.023	CcSEcCtD
Levomilnacipran—Endocrine disorder—Varenicline—nicotine dependence	0.0148	0.0209	CcSEcCtD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0145	0.0521	CbGpPWpGaD
Levomilnacipran—CYP2J2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0143	0.0515	CbGpPWpGaD
Levomilnacipran—Pethidine—OPRM1—nicotine dependence	0.0141	1	CrCbGaD
Levomilnacipran—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0141	0.0506	CbGpPWpGaD
Levomilnacipran—Aggression—Varenicline—nicotine dependence	0.0139	0.0197	CcSEcCtD
Levomilnacipran—Chest discomfort—Varenicline—nicotine dependence	0.0138	0.0196	CcSEcCtD
Levomilnacipran—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0136	0.0192	CcSEcCtD
Levomilnacipran—Ventricular extrasystoles—Varenicline—nicotine dependence	0.0136	0.0192	CcSEcCtD
Levomilnacipran—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0126	0.0451	CbGpPWpGaD
Levomilnacipran—Blood pressure increased—Varenicline—nicotine dependence	0.0123	0.0173	CcSEcCtD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0118	0.0423	CbGpPWpGaD
Levomilnacipran—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0115	0.0415	CbGpPWpGaD
Levomilnacipran—Dry eye—Varenicline—nicotine dependence	0.0113	0.016	CcSEcCtD
Levomilnacipran—Renal failure acute—Varenicline—nicotine dependence	0.00964	0.0136	CcSEcCtD
Levomilnacipran—Libido decreased—Varenicline—nicotine dependence	0.00959	0.0136	CcSEcCtD
Levomilnacipran—Hot flush—Varenicline—nicotine dependence	0.00951	0.0134	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Varenicline—nicotine dependence	0.00943	0.0133	CcSEcCtD
Levomilnacipran—Thirst—Varenicline—nicotine dependence	0.00935	0.0132	CcSEcCtD
Levomilnacipran—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00901	0.0324	CbGpPWpGaD
Levomilnacipran—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00883	0.0125	CcSEcCtD
Levomilnacipran—Migraine—Varenicline—nicotine dependence	0.00876	0.0124	CcSEcCtD
Levomilnacipran—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.00872	0.0313	CbGpPWpGaD
Levomilnacipran—Irritability—Varenicline—nicotine dependence	0.00849	0.012	CcSEcCtD
Levomilnacipran—Urinary retention—Varenicline—nicotine dependence	0.00846	0.012	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Varenicline—nicotine dependence	0.00821	0.0116	CcSEcCtD
Levomilnacipran—Dry skin—Varenicline—nicotine dependence	0.00815	0.0115	CcSEcCtD
Levomilnacipran—Breast disorder—Varenicline—nicotine dependence	0.00804	0.0114	CcSEcCtD
Levomilnacipran—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00778	0.028	CbGpPWpGaD
Levomilnacipran—Abdominal distension—Varenicline—nicotine dependence	0.00774	0.0109	CcSEcCtD
Levomilnacipran—Angina pectoris—Varenicline—nicotine dependence	0.00749	0.0106	CcSEcCtD
Levomilnacipran—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00716	0.0257	CbGpPWpGaD
Levomilnacipran—Pollakiuria—Varenicline—nicotine dependence	0.0071	0.01	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Varenicline—nicotine dependence	0.00708	0.01	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.0068	0.0096	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00663	0.0238	CbGpPWpGaD
Levomilnacipran—Hepatobiliary disease—Varenicline—nicotine dependence	0.00648	0.00916	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—CYP2A7—nicotine dependence	0.00625	0.0225	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00616	0.0221	CbGpPWpGaD
Levomilnacipran—Hypoaesthesia—Varenicline—nicotine dependence	0.00612	0.00865	CcSEcCtD
Levomilnacipran—Hallucination—Varenicline—nicotine dependence	0.00612	0.00865	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Varenicline—nicotine dependence	0.00608	0.00859	CcSEcCtD
Levomilnacipran—Oedema peripheral—Varenicline—nicotine dependence	0.00606	0.00857	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Varenicline—nicotine dependence	0.00605	0.00854	CcSEcCtD
Levomilnacipran—Urethral disorder—Varenicline—nicotine dependence	0.00603	0.00852	CcSEcCtD
Levomilnacipran—Erythema multiforme—Varenicline—nicotine dependence	0.00582	0.00822	CcSEcCtD
Levomilnacipran—Eye disorder—Varenicline—nicotine dependence	0.00575	0.00813	CcSEcCtD
Levomilnacipran—Cardiac disorder—Varenicline—nicotine dependence	0.00571	0.00807	CcSEcCtD
Levomilnacipran—Angiopathy—Varenicline—nicotine dependence	0.00558	0.00789	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Varenicline—nicotine dependence	0.00555	0.00784	CcSEcCtD
Levomilnacipran—Chills—Varenicline—nicotine dependence	0.00552	0.0078	CcSEcCtD
Levomilnacipran—Mental disorder—Varenicline—nicotine dependence	0.00539	0.00762	CcSEcCtD
Levomilnacipran—Malnutrition—Varenicline—nicotine dependence	0.00536	0.00757	CcSEcCtD
Levomilnacipran—Flatulence—Varenicline—nicotine dependence	0.00528	0.00746	CcSEcCtD
Levomilnacipran—Dysgeusia—Varenicline—nicotine dependence	0.00525	0.00741	CcSEcCtD
Levomilnacipran—Vision blurred—Varenicline—nicotine dependence	0.00505	0.00713	CcSEcCtD
Levomilnacipran—Tremor—Varenicline—nicotine dependence	0.00502	0.00709	CcSEcCtD
Levomilnacipran—Agitation—Varenicline—nicotine dependence	0.00492	0.00696	CcSEcCtD
Levomilnacipran—Syncope—Varenicline—nicotine dependence	0.0048	0.00679	CcSEcCtD
Levomilnacipran—Palpitations—Varenicline—nicotine dependence	0.00473	0.00669	CcSEcCtD
Levomilnacipran—Loss of consciousness—Varenicline—nicotine dependence	0.00471	0.00665	CcSEcCtD
Levomilnacipran—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00468	0.0168	CbGpPWpGaD
Levomilnacipran—Convulsion—Varenicline—nicotine dependence	0.00464	0.00656	CcSEcCtD
Levomilnacipran—Hypertension—Varenicline—nicotine dependence	0.00463	0.00653	CcSEcCtD
Levomilnacipran—Chest pain—Varenicline—nicotine dependence	0.00456	0.00644	CcSEcCtD
Levomilnacipran—Anxiety—Varenicline—nicotine dependence	0.00454	0.00642	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00453	0.0064	CcSEcCtD
Levomilnacipran—Dry mouth—Varenicline—nicotine dependence	0.00446	0.0063	CcSEcCtD
Levomilnacipran—Infection—Varenicline—nicotine dependence	0.00434	0.00614	CcSEcCtD
Levomilnacipran—Shock—Varenicline—nicotine dependence	0.0043	0.00608	CcSEcCtD
Levomilnacipran—Nervous system disorder—Varenicline—nicotine dependence	0.00429	0.00606	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Varenicline—nicotine dependence	0.00428	0.00605	CcSEcCtD
Levomilnacipran—Tachycardia—Varenicline—nicotine dependence	0.00427	0.00603	CcSEcCtD
Levomilnacipran—Skin disorder—Varenicline—nicotine dependence	0.00425	0.006	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Varenicline—nicotine dependence	0.00423	0.00597	CcSEcCtD
Levomilnacipran—Anorexia—Varenicline—nicotine dependence	0.00417	0.00589	CcSEcCtD
Levomilnacipran—Hypotension—Varenicline—nicotine dependence	0.00409	0.00577	CcSEcCtD
Levomilnacipran—Insomnia—Varenicline—nicotine dependence	0.00395	0.00559	CcSEcCtD
Levomilnacipran—Dyspnoea—Varenicline—nicotine dependence	0.0039	0.00551	CcSEcCtD
Levomilnacipran—Somnolence—Varenicline—nicotine dependence	0.00389	0.00549	CcSEcCtD
Levomilnacipran—Dyspepsia—Varenicline—nicotine dependence	0.00385	0.00544	CcSEcCtD
Levomilnacipran—Decreased appetite—Varenicline—nicotine dependence	0.0038	0.00537	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00377	0.00533	CcSEcCtD
Levomilnacipran—Fatigue—Varenicline—nicotine dependence	0.00377	0.00533	CcSEcCtD
Levomilnacipran—Constipation—Varenicline—nicotine dependence	0.00374	0.00528	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00372	0.0134	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00362	0.013	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Varenicline—nicotine dependence	0.00358	0.00505	CcSEcCtD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00357	0.0128	CbGpPWpGaD
Levomilnacipran—Urticaria—Varenicline—nicotine dependence	0.00347	0.00491	CcSEcCtD
Levomilnacipran—Abdominal pain—Varenicline—nicotine dependence	0.00346	0.00488	CcSEcCtD
Levomilnacipran—Body temperature increased—Varenicline—nicotine dependence	0.00346	0.00488	CcSEcCtD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00323	0.0116	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Varenicline—nicotine dependence	0.00322	0.00455	CcSEcCtD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00319	0.0115	CbGpPWpGaD
Levomilnacipran—Asthenia—Varenicline—nicotine dependence	0.00314	0.00443	CcSEcCtD
Levomilnacipran—Pruritus—Varenicline—nicotine dependence	0.00309	0.00437	CcSEcCtD
Levomilnacipran—Diarrhoea—Varenicline—nicotine dependence	0.00299	0.00423	CcSEcCtD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00297	0.0107	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00294	0.0106	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00293	0.0105	CbGpPWpGaD
Levomilnacipran—Dizziness—Varenicline—nicotine dependence	0.00289	0.00408	CcSEcCtD
Levomilnacipran—Vomiting—Varenicline—nicotine dependence	0.00278	0.00393	CcSEcCtD
Levomilnacipran—Rash—Varenicline—nicotine dependence	0.00276	0.00389	CcSEcCtD
Levomilnacipran—Dermatitis—Varenicline—nicotine dependence	0.00275	0.00389	CcSEcCtD
Levomilnacipran—Headache—Varenicline—nicotine dependence	0.00274	0.00387	CcSEcCtD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00262	0.00942	CbGpPWpGaD
Levomilnacipran—Nausea—Varenicline—nicotine dependence	0.0026	0.00367	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00248	0.00892	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00241	0.00866	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00225	0.0081	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00203	0.00728	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00194	0.00699	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00192	0.0069	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00165	0.00595	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00158	0.00566	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00156	0.00561	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00154	0.00553	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—DRD2—nicotine dependence	0.0015	0.00538	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00148	0.00531	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00139	0.005	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00137	0.00493	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00136	0.00488	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00128	0.0046	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00126	0.00454	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00113	0.00405	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP2A7—nicotine dependence	0.00107	0.00384	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000888	0.00319	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000837	0.00301	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000825	0.00297	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000496	0.00178	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000267	0.000959	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000238	0.000856	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000232	0.000835	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000219	0.000787	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000143	0.000515	CbGpPWpGaD
